Diary - News
All news ENYO Pharma SA announces successful completion of EYP001 first in man Phase 1 study
Lyon, June 14, 2017 - ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1a single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been completed. The results show that EYP001 was safe and well-tolerated at all doses studied in 80 subjects.
Read the press release